Cross-sensitivity between taxanes in patients with breast cancer

Clinical and Translational Oncology

Volumn 13, Issue 12, 2011, Pages 904-906

  Sánchez Muñoz, Alfonso ^a   Jiménez, Begoña ^a   García Tapiador, Ana ^b   Romero García, Gema ^a   Medina, Laura ^a   Navarro, Víctor ^a   González Sánchez, Luis Alonso ^b   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

Author keywords

Cross reaction; Cross resistance; Docetaxel; Hypersensitivity reaction; Paclitaxel

Indexed keywords

DEXAMETHASONE; DEXCHLORPHENIRAMINE; DOCETAXEL; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CONTROLLED STUDY; DESENSITIZATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PREMEDICATION; RETROSPECTIVE STUDY; RISK REDUCTION;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEXAMETHASONE; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PACLITAXEL; PREMEDICATION; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 84856038481     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0753-3     Document Type: Article

References (12)

1. Crown J, O'Leary M, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9[Suppl 2]:24-32 (Pubitemid 38747840)
2. Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8:1263-1268 (Pubitemid 20195638)
3. Dizon DS, Schwartz J, Rojan A et al (2006) Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol Oncol 100:149-151 (Pubitemid 41815065)
4. Moon C, Verschraegen CF, Bevers M Et al (2000) Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs 11:565-568
5. Lokich J, Anderson N (1998) Paclitaxel hypersensitivity reactions: a role for docetaxel substitution. Ann Oncol 9:573
6. Denman JP, Gilbar PJ, Abdi EA (2002) Hypersensitivity reaction (HSR) to docetaxel after a previous HSR to paclitaxel. J Clin Oncol 20:2760-2761 (Pubitemid 34575656)
7. Essayan DM, Kagey-Sobotka A, Colarusso PJ et al (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42-46 (Pubitemid 26045967)
8. Feldweg AM, Lee CW, Matulonis UA, Castells M (2005) Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 96:824-829 (Pubitemid 40255508)
9. Fishman A, Gold T, Goldberg A et al (1999) Effective desensitization protocol to paclitaxel following hypersensitivity reaction. Int J Gynecol Cancer 9:156-159 (Pubitemid 29220754)
10. Castells MC, Tennant NM, Sloane DE et al (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122:574-580
11. Gradishar WJ, Tjulandin S, Davidson N et al (2005) Phase III trial of nanoparticle albuminbound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803 (Pubitemid 46657376)
12. Gradishar WJ, Krasnojon D, Cheporov S et al (2009) Signifi cantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27:3611-3619